“Idongivafumab’s unique ability to target and inhibit C-suite peptides, as well the entire electronic health record (EHR) cascade, represents a quantum leap in burnout science,” Palmer explained in a statement.
“Clinical test subjects also noted a marked decrease in symptoms of Entitled Patient Pruritus (EPP) during the course of treatment. Some 87% of those treated stated they felt ready to type at a keyboard with their back to the patient; feeling a need to apply to law school, write a novel, or sell crafts on Etsy fell by a whopping 98%. This drug may truly revolutionize health care.”
Please remove the picture as this constitutes copyright infringement. This is drawn and published by Drizzle MD. The picture can only be used if a link is included into the text that leads to the following page https://drizzlemd.com/2018/02/19/chasing-the-numbers/
My apologies for not investigating further and asking permission. The pic has been removed.